A Phase III Psoriasis and Pruritus Trial of SNA-120
Phase of Trial: Phase III
Latest Information Update: 14 Mar 2019
At a glance
- Drugs Pegcantratinib (Primary)
- Indications Pruritus; Psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Sienna Biopharmaceuticals
- 14 Mar 2019 According to a Sienna Biopharmaceuticals media release, following an end-of-phase 2 (EOP2) meeting with FDA the company plans to initiate this trial is expected to commence in the second half of 2019.
- 03 Dec 2018 According to a Sienna Biopharmaceuticals media release, the company expect to start this phase 3 study for psoriasis in the second half of 2019.
- 20 May 2013 New trial record